Biosimilars

Biosimilars, biogenerics or follow-on biologics - by any name, second generation versions of blockbuster biologic products are coming to America and they are going to have a profound impact on all aspects of the pharmaceutical industry. Now, VOI Consulting, publisher of PharmaHandbook and GenericHandbook, is offering Biosimilars: Problems, Prospects and Projections, a single-source analysis of this fast-moving topic, for immediate download. For only $337, this 55-page PDF report, written in April 2009, provides current information on the economic, manufacturing, regulatory, legislative, competitive and marketing issues that make biosimilars such a lucrative but challenging opportunity. Although focused on the U.S., the report also examines developments in Japan, Canada, Australia, India and China. Experiences in the European Union, which has the most advanced biosimilar sector, are given special attention. An appendix provides summaries and links to a dozen recent economic, scientific and commercial studies on the subject. Biosimilars are already changing business models and bringing in a whole new set of competitors. Download Biosimilars: Problems, Prospects and Projections today and get out in front of what is certain to be one of the industry-transforming issues of the coming decade.